722 related articles for article (PubMed ID: 29266249)
1. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
2. Complement associated pathogenic mechanisms in myasthenia gravis.
Tüzün E; Christadoss P
Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
[TBL] [Abstract][Full Text] [Related]
3. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
6. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
7. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
8. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
9. Cell surface complement regulators moderate experimental myasthenia gravis pathology.
Kusner LL; Halperin JA; Kaminski HJ
Muscle Nerve; 2013 Jan; 47(1):33-40. PubMed ID: 23042232
[TBL] [Abstract][Full Text] [Related]
10. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies.
Plomp JJ; Huijbers MGM; Verschuuren JJGM; Borodovsky A
J Neurosci Methods; 2022 May; 373():109551. PubMed ID: 35247492
[TBL] [Abstract][Full Text] [Related]
11. Targeting complement system to treat myasthenia gravis.
Huda R; Tüzün E; Christadoss P
Rev Neurosci; 2014; 25(4):575-83. PubMed ID: 24731953
[TBL] [Abstract][Full Text] [Related]
12. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
13. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
[TBL] [Abstract][Full Text] [Related]
14. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis: State of the art and new therapeutic strategies.
Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
[TBL] [Abstract][Full Text] [Related]
16. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
17. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
[TBL] [Abstract][Full Text] [Related]
18. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
[TBL] [Abstract][Full Text] [Related]
19. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G; Putko BN; Wagner AN; Siddiqi ZA
Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]